MOLN

NASDAQ open

Molecular Partners AG

2.56 USD
0.000.00%
盘后 2.56 0.00%
2026-11-19
市值
$93.64M
市盈率
—
EPS
-1.60
股息率
—
52 周区间
2.56 – 5.36
成交量
22.00
Beta
0.61
目标价
9.97
52W 低 2.5652W 高 5.36
价格走势

公司简介

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...